Learn the mechanism, types, and doses of soluble fiber that have been shown to be beneficial for preventing ASCVD and diabetes risk factors, and discover how to easily incorporate soluble fiber in your patients’ diet. 

Learning Objectives

  • Describe the role of dietary and supplemental soluble fiber in preventing atherosclerotic cardiovascular disease and type 2 diabetes risks
  • Describe the doses, mechanisms and types of soluble fiber for preventing atherosclerotic cardiovascular disease and type 2 diabetes risks
  • Discuss how to integrate soluble fiber in your patients’ diet 

Faculty Disclosures

Stephen Kopecky, MD

Consultant: Prime Therapeutic; Pfizer
Contracted Research: Amgen, Regeneron
Chair Data Safety: Monitor Board Member/Member, BOD Applied Clinical Intelligence; American Society for Men’s Health; Mayo Clinic Support Services, Texas; Mayo Clinic CV P&T Taskforce

John Miles, MD

No financial relationships to disclose. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Commercial Supporter

Procter & Gamble 

Education Partner

American Society for Preventive Cardiology

Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and ASPC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. 

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

It is the policy of ASPC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ASPC and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.  AKH planners and reviewers have no relevant financial relationships to disclose.